Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Hyundai Bioscience announced on April 25th that its clinical development plan of oral “Niclosamide Metabolic Anticancer Drug” targeting cancer patients with intractable cancer caused by p53 gene mutations. Mutations in the p53 gene occur in almost all cancer types and cause intractable…